Extensive long-standing chromomycosis due to Fonsecaea pedrosoi: Three cases with relevant improvement under voriconazole therapy

Journal of Dermatological Treatment

Volumn 22, Issue 3, 2011, Pages 167-174

  Criado, Paulo Ricardo ^a   Careta, Mariana Figueiroa ^a   Valente, Neusa Y S ^a   Martins, José Eduardo Costa ^a   Rivitti, Evandro A ^a   Spina, Ricardo ^a   Belda Jr , Walter ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

chromomycosis; fungal skin diseases; itraconazole; terbinafine; voriconazole

Indexed keywords

AMPHOTERICIN B; ITRACONAZOLE; POSACONAZOLE; TERBINAFINE; VORICONAZOLE;

ABNORMAL VISION; ADULT; AGED; AGITATION; AGRICULTURAL WORKER; ANTIMICROBIAL THERAPY; ARTICLE; CASE REPORT; CAUCASIAN; CHROMOMYCOSIS; CRYOTHERAPY; DRUG DOSE REDUCTION; DRUG WITHDRAWAL; FONSECAEA PEDROSOI; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; HEPATITIS C; HISTOPATHOLOGY; HUMAN; LIVER FUNCTION TEST; MALE; MENTAL DISEASE; PHOTOSENSITIVE DERMATITIS; PRIORITY JOURNAL; SIDE EFFECT; SKIN BIOPSY; SKIN DISEASE; TRANSMISSION ELECTRON MICROSCOPY; TREATMENT RESPONSE; TREMOR; VERRUCOUS PLAQUE;

ADULT; AGED; ANTIFUNGAL AGENTS; ASCOMYCOTA; CHROMOBLASTOMYCOSIS; HUMANS; MALE; MIDDLE AGED; PYRIMIDINES; TRIAZOLES;

EID: 79957467891     PISSN: 09546634     EISSN: 14711753     Source Type: Journal    
DOI: 10.3109/09546630903585074     Document Type: Article

References (23)

1. Paniz-Mondolfi AE, Colella MT, Negrín DC, Aranzazu N, Oliver M, Reyes-Jaimes O, et al. Extensive chromoblastomycosis caused by Fonsecaea pedrosoi successfully treated with a combination of amphotericin B and itraconazole. Med Mycol. 2008;46(2):179-184 (Pubitemid 351372339)
2. Sayal SK, Prasad GK, Jawed KZ, Sanghi S, Satyanarayana S. Chromoblastomycosis. Indian J Dermatol Venereol Leprol. 2002;68:233-234
3. Franzen AJ, Cunha MM,Miranda K, Hentschel J, Plattner H, da Silva MB, et al. Ultrastructural characterization of melanosomes of the human pathogenic fungus Fonsecaea pedrosoi. J Struct Biol. 2008;162(1):75-84
4. DamianDL,BarnetsonRS,Thompson JF.Treatment of refractory chromomycosis by isolated limb infusion with melphalan and actinomycin D. J Cutan Med Surg. 2006;10(1):48-51 (Pubitemid 351506631)
5. Gimenes VM, Criado PR, Martins JE, Almeida SR. Cellular immune response of patients with chromoblastomycosis undergoing antifungal therapy. Mycopathologia. 2006; 162(2):97-101 (Pubitemid 44188072)
6. Tuffanelli I, Milburn PB. Treatment of chromoblastomycosis. J Am Acad Dermotol. 1991;25(5 Pt 1):869-870
7. Smith C, Barker J, Hay R. A case of chromoblastomycosis responding to treatment with itraconazole. Br J Dermatol. 1993;128:436-439 (Pubitemid 23105900)
8. Queiroz-Telles F, Purim KS, Fillus JN, Bordignon GF, Lameira RP, Van Cutsem J, Cauwenbergh G. Itraconazole in the treatment of chromoblastomycosis due to Fonsecaea pedrosoi. Int J Dermatol. 1992;31:805-812
9. Andrade TS, Castro LG, Nunes RS, Gimenes VM, Cury AE. Susceptibility of sequential Fonsecaea pedrosoi isolates from chromoblastomycosis patients to antifungal agents. Mycoses. 2004;47:216-221 (Pubitemid 38903453)
10. Esterre P, Queiroz-Telles F. Management of chromoblastomycosis: Novel perspectives. Curr Opin Infect Dis. 2006; 19(2):148-152 (Pubitemid 44139144)
11. Hazen KC. Fungicidal versus fungistatic activity of terbinafine and itraconazole: An in vitro comparison. J Am Acad Dermatol. 1998;38:37-41
12. Gupta AK, Taborda PR, Danzovo AD. Alternate week and combination itraconazole and terbinafine therapy for chromoblastomycosis caused by Fonsecaea pedrosoi in Brazil. Med Mycol. 2002;40:529-534 (Pubitemid 35363486)
13. Bonifaz A, Paredes-Sólis V, Saul A. Treating chromoblastomycosis with systemic antifungals. Expert Opin Pharmacother. 2004;5:247-254 (Pubitemid 38219852)
14. Queiroz-Telles F, McGinnis MR, Salkin I, Graybill JR. Subcutaneous mycoses. Infect Dis Clin North Am. 2003;17(1): 59-85 (Pubitemid 36514571)
15. Maertens JA. History of the development of azole derivatives. Clin Microbiol Infect. 2004;10(suppl 1):1-10 (Pubitemid 38379948)
16. Hamza SH, Mercado PJ, Skelton HG, Smith KJ. An unusual dematiaceous fungal infection of the skin caused by Fonsecaea pedrosoi: A case report and review of the literature. J Cutan Pathol. 2003;30(5):340-343 (Pubitemid 36648911)
17. Surash S, Tyagi A, De Hoog GS, Zeng JS, Barton RC, Hobson RP. Cerebral phaeohyphomycosis caused by Fonsecaea monophora. Med Mycol. 2005;43(5): 465-472 (Pubitemid 41283051)
18. Perfect J, Marr KA, Walsh TJ, Greenberg RN, DuPont B, de la Torre-Cisneros J, Just-Nübling G, Schlamm HT, Lutsar I, Espinel-Ingroff A, Johnson E. Voriconazole treatment for less-common, emerging, or refractory fungal infections. Clin Infect Dis. 2003;36:1122-1131 (Pubitemid 36549632)
19. Paugam A. The latest data on posaconazole. Med Mal Infect. 2007;37(2):71-76
20. Jurkunas UV, Langston DP, Colby K. Use of voriconazole in the treatment of fungal keratitis. Int Ophthalmol Clin. 2007;47(2):47-59 (Pubitemid 46725803)
21. Da Silva JP, Alviano DS, Alviano CS, de Souza W, Travassos LR,Diniz JA, et al. Comparison of Fonsecaea pedrosoi sclerotic cells obtained in vivo and in vitro: Ultrastructure and antigenicity. FEMS Immunol MedMicrobiol. 2002;33(1):63-69 (Pubitemid 34461927)
22. Sabo JA, Abdel-Rahman SM. Voriconazole: A new traizole antifungal. Ann Pharmacother. 2000;34:1032-1043
23. Johnson L, Kauffman C. Voriconazole: A new triazole antifungal agent. Clin Infect Dis. 2003;36:630-637 (Pubitemid 36259570)